GinaZD'AmatoMD

Oncology • Miami, FL

Hematologic Oncology, Sarcoma

Associate Professor of Medicine Sarcoma Medical Oncology Assistant Director of Clinical Research Medical Director of Comprehensive Treatment Unit Sylvester Comprehensive Cancer Center/University of Miami Health System

Join to view full profile

Dr. D'Amato is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. D'Amato's full profile

Already have an account?

Office
Sylvester Comprehensive Cancer Center/University of Miami Health System
1120 NW 14th St Suite 610
Miami, FL 33136
Phone+1 305-243-2581

Fax+1 305-243-9161

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
University of Miami Leonard M. Miller School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2003 - 2025
GA State Medical License 2008 - 2019

Awards, Honors, & Recognition

Atlanta Magazine: Top Doctors Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013

Clinical Trials

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

18 citations
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
John Zalcberg, Michael Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski
The Oncologist. 2021-11-01
35 citations
Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis.
Andrea P. Espejo-Freire, Andrew Elliott, Andrew E. Rosenberg, Philippos Apolinario Costa, Priscila Barreto-Coelho
Cancers. 2021-09-26
21 citations
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
Sebastian Bauer, Michael Heinrich, Suzanne George, John Zalcberg, César Serrano
Clinical Cancer Research. 2021-09-09